Regulatory T-cells, method for their isolation and uses
The invention pertains to methods of isolating a Treg from a subject, the method comprising the steps of analyzing a sample of cells obtained from the subject to determine the level of expression of polypeptides and/or polynucleotides corresponding to proteins CD 127, CD4, CD25, and CD226 and isolating, as the Treg, a cell which expresses CD4 and CD25, expresses low levels of CD 127 or does not express CD 127, and expresses low levels of CD226 or does not express CD226. The Treg isolated from a subject can be proliferated in vitro. Accordingly, the invention also provides compositions comprising Treg isolated/proliferated according to the methods of the invention and pharmaceutically acceptable carrier and/or excipient. The pharmaceutical compositions can be used to treat and/or prevent inflammation mediated disease, for example, autoimmune diseases, such as, systemic lupus erythmatosus, rheumatoid arthritis, Multiple Sclerosis, type 1 diabetes, or inflammatory bowel disease.
1. A method for isolating a regulatory T cell (Treg) from a subject, the method comprising the steps of:
a) analyzing a sample of cells obtained from the subject to determine the level of expression of polypeptides and/or polynucleotides corresponding to proteins CD4, CD25, CD226, and CD127, and
b) isolating, as the Treg, a cell which:
i) expresses CD4 and CD25, and
ii expresses low levels of CD127 or does not express CD127, and/or
iii expresses low levels of CD226 or does not express CD226.
2. The method of claim 1 , wherein the method comprises analyzing the level of expression proteins CD127, CD4, CD25, and CD226.
3. The method of claim 2 , wherein the step of isolating comprises isolating the cell which:
i) expresses CD4 and CD25,
ii) expresses low levels of CD127 or does not express CD127, and
iii) expresses low levels of CD226 or does not express CD226.
4. The method of claim 2 , wherein the step of isolating comprises isolating the cell which:
i) expresses CD4 and CD25,
ii) expresses low levels of CD127 or does not express CD127, and
iv) does not express CD226.
5. The method of claim 1 , wherein the step of isolating comprises isolating the cell which:
i) expresses CD4 and CD25, and
iii) expresses low levels of CD226 or does not express CD226.
6. The method according to claim 1 , wherein the step of analyzing the level of expression proteins comprises the steps of:
(A) obtaining the sample of cells from the subject;
(B) contacting the sample of cells with antibodies directed towards CD4, CD25, and CD226 to allow binding of the antibodies to the corresponding proteins;
(C) subjecting the sample of cells to flow cytometry;
(D) examining the flow cytometry signal for the expression of CD4, CD25, and CD226, and
(E) isolating, as the Treg, the cell which: i) expresses CD4 and CD25, and iii) expresses low levels of CD226 or does not express CD226.
7. The method of claim 1 , the method further comprises proliferating the Treg in vitro.
8. A method according to claim 7 , further comprising administering the Treg to the subject.